Nations Financial Group Inc. IA ADV Takes Position in United Therapeutics Co. (NASDAQ:UTHR)

Nations Financial Group Inc. IA ADV acquired a new position in United Therapeutics Co. (NASDAQ:UTHRFree Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 1,041 shares of the biotechnology company’s stock, valued at approximately $229,000.

Several other institutional investors have also recently made changes to their positions in UTHR. GAMMA Investing LLC purchased a new stake in United Therapeutics during the 4th quarter valued at approximately $43,000. C M Bidwell & Associates Ltd. purchased a new position in United Therapeutics during the third quarter valued at $91,000. Blue Trust Inc. increased its holdings in United Therapeutics by 10.0% in the 4th quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock valued at $114,000 after acquiring an additional 46 shares during the last quarter. Quadrant Capital Group LLC lifted its stake in United Therapeutics by 31.2% in the 4th quarter. Quadrant Capital Group LLC now owns 581 shares of the biotechnology company’s stock worth $128,000 after purchasing an additional 138 shares in the last quarter. Finally, CWM LLC boosted its holdings in shares of United Therapeutics by 45.7% during the 4th quarter. CWM LLC now owns 670 shares of the biotechnology company’s stock valued at $147,000 after purchasing an additional 210 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Trading Down 1.4 %

UTHR stock opened at $269.15 on Wednesday. United Therapeutics Co. has a twelve month low of $204.44 and a twelve month high of $279.98. The stock has a market capitalization of $11.94 billion, a price-to-earnings ratio of 12.73, a price-to-earnings-growth ratio of 4.13 and a beta of 0.54. The company has a quick ratio of 3.64, a current ratio of 3.77 and a debt-to-equity ratio of 0.04. The firm’s fifty day simple moving average is $248.67 and its two-hundred day simple moving average is $234.76.

United Therapeutics (NASDAQ:UTHRGet Free Report) last issued its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 EPS for the quarter, beating the consensus estimate of $5.63 by $0.54. The company had revenue of $677.70 million for the quarter, compared to the consensus estimate of $620.31 million. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The firm’s revenue was up 33.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $4.86 EPS. As a group, analysts anticipate that United Therapeutics Co. will post 24.2 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. JPMorgan Chase & Co. lifted their target price on United Therapeutics from $280.00 to $300.00 and gave the stock an “overweight” rating in a report on Tuesday, May 21st. Wells Fargo & Company upped their price objective on United Therapeutics from $309.00 to $325.00 and gave the stock an “overweight” rating in a report on Thursday, March 7th. HC Wainwright reiterated a “buy” rating and set a $300.00 target price on shares of United Therapeutics in a research report on Thursday, May 2nd. The Goldman Sachs Group boosted their price target on shares of United Therapeutics from $218.00 to $240.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. Finally, Oppenheimer increased their price objective on shares of United Therapeutics from $375.00 to $400.00 and gave the company an “outperform” rating in a research report on Thursday, May 2nd. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $309.44.

Get Our Latest Stock Analysis on United Therapeutics

Insider Transactions at United Therapeutics

In related news, Director Christopher Causey sold 2,240 shares of the business’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $259.91, for a total transaction of $582,198.40. Following the completion of the transaction, the director now owns 4,185 shares in the company, valued at approximately $1,087,723.35. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, Director Christopher Causey sold 2,240 shares of United Therapeutics stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $259.91, for a total transaction of $582,198.40. Following the completion of the sale, the director now owns 4,185 shares in the company, valued at approximately $1,087,723.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Nilda Mesa sold 325 shares of the business’s stock in a transaction dated Wednesday, March 27th. The shares were sold at an average price of $237.80, for a total transaction of $77,285.00. Following the completion of the sale, the director now directly owns 5,373 shares of the company’s stock, valued at $1,277,699.40. The disclosure for this sale can be found here. Over the last three months, insiders have sold 157,128 shares of company stock worth $38,053,129. 12.50% of the stock is currently owned by company insiders.

About United Therapeutics

(Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Recommended Stories

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHRFree Report).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.